Brokerages Set Astrana Health, Inc. (NASDAQ:ASTH) Target Price at $65.17

Shares of Astrana Health, Inc. (NASDAQ:ASTH) have earned an average rating of “Buy” from the eight brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $65.17.

A number of research firms recently weighed in on ASTH. KeyCorp began coverage on Astrana Health in a research report on Friday, October 11th. They set a “sector weight” rating for the company. Robert W. Baird lifted their price target on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. TD Cowen initiated coverage on shares of Astrana Health in a research note on Monday, October 14th. They set a “buy” rating and a $66.00 price objective for the company. Stifel Nicolaus boosted their target price on Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Finally, Truist Financial raised their price target on shares of Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a report on Friday, August 9th.

Astrana Health Price Performance

ASTH opened at $42.11 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The company has a market cap of $2.37 billion, a price-to-earnings ratio of 32.39, a price-to-earnings-growth ratio of 1.95 and a beta of 1.24. The stock has a fifty day simple moving average of $54.17 and a two-hundred day simple moving average of $47.94. Astrana Health has a 12-month low of $32.32 and a 12-month high of $63.20.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The company had revenue of $478.71 million during the quarter, compared to analyst estimates of $462.01 million. During the same period last year, the business earned $0.47 EPS. Research analysts predict that Astrana Health will post 1.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Astrana Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC purchased a new position in shares of Astrana Health in the third quarter valued at about $34,000. Nisa Investment Advisors LLC bought a new position in Astrana Health in the 3rd quarter worth approximately $35,000. KBC Group NV purchased a new stake in Astrana Health during the 3rd quarter valued at approximately $70,000. Quarry LP bought a new stake in shares of Astrana Health during the third quarter valued at approximately $77,000. Finally, Quest Partners LLC bought a new stake in Astrana Health in the 3rd quarter valued at $133,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.